Company Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases.
The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors.
It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases.
It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa’s mrna vaccine ecosystem.
BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.
| Country | Germany |
| Founded | 2008 |
| IPO Date | Oct 10, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6,772 |
| CEO | Ugur Sahin |
Contact Details
Address: An der Goldgrube 12 Mainz, 55131 Germany | |
| Phone | 49 6131 9084 0 |
| Website | biontech.de |
Stock Details
| Ticker Symbol | BNTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $15.00 |
| CIK Code | 0001776985 |
| CUSIP Number | 09075V102 |
| ISIN Number | US09075V1026 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ugur Sahin M.D. | Co-Founder, Chief Executive Officer and Chair of the Management Board |
| Dr. Ozlem Tureci M.D. | Co-Founder, Chief Medical Officer and Member of Management Board |
| Jens H. Holstein | Chief Financial Officer and Member of Management Board |
| Dr. Sierk Poetting Ph.D. | MD, Chief Operating Officer and Member of Management Board |
| Ryan Richardson | Chief Strategy Officer, MD and Member of Management Board |
| Dr. James Timothy Patrick Ryan Ph.D. | Chief Legal and Business Officer & Member of the Management Board |
| Annemarie Hanekamp | Chief Commercial Officer and Member of Management Board |
| Lisa Birringer | Senior Vice President of Global Financial Reporting and Accounting |
| Zach Taylor | Senior Vice President of Corporate Development and Strategy |
| Beate Berns | Senior Vice President of Global Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 10, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Mar 10, 2025 | 6-K | Report of foreign issuer |
| Mar 4, 2025 | 6-K | Report of foreign issuer |
| Feb 27, 2025 | 144 | Filing |
| Feb 20, 2025 | 144 | Filing |
| Feb 20, 2025 | 144 | Filing |
| Feb 3, 2025 | 6-K | Report of foreign issuer |
| Jan 14, 2025 | 6-K | Report of foreign issuer |
| Dec 27, 2024 | 6-K | Report of foreign issuer |
| Dec 27, 2024 | 6-K | Report of foreign issuer |